Skip to main content
. Author manuscript; available in PMC: 2024 Jun 20.
Published in final edited form as: Nature. 2023 Dec 6;625(7993):166–174. doi: 10.1038/s41586-023-06797-9

Figure 4. IL-4Rα blockade enhances response to immunotherapy in human NSCLC.

Figure 4.

(a) Lung tumor burden in mice transplanted with HKP1 cells and treated with αPD-L1 antibodies, αIL-4 antibodies, or a combination of both (n=8, 8, 10, 10 mice per group). Pooled from two independent experiments. (b) Clinical trial design. (c) Averaged heatmap of Olink Inflammation Panel analytes in patients’ plasma at indicated timepoints post dupilumab treatment. (d) Levels of indicated immune cells in patient whole blood at indicated timepoints post dupilumab treatment as assessed by CyTOF, normalized to Day 1 (pre-dupilumab treatment). Dotted lines represent individual patients; solid line represents mean of all patients. (e) Number of CD8, DC-LAMP, and CD20-positve cells in tumor biopsies of relapsed/refractory NSCLC patients prior to and 36 days after initiation of dupilumab treatment, as measured by IHC (n=3 patients). Scale bar=50μm. (f) Chest CT stans of dupilumab responder patient before treatment and 56, 168, and 273 days after treatment. One way ANOVA with post hoc Tukey’s multiple comparison test (a). Panels b-f representative of one clinical cohort.